CARLSBAD, Calif., May 6 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company developing
immune-based therapies (IBT) for HIV and select other diseases, will present
at the Rodman & Renshaw Techvest Global Healthcare Conference in London.
Chief Executive Officer John N. Bonfiglio, Ph.D., will make his presentation
on Thursday, May 13, 2004, at 10:35 a.m. GMT.
A live webcast of the audio presentation will be available along with
accompanying presentation slides. Interested parties may tune in to the live
presentation by visiting the Company's website at http://www.imnr.com at 3:35 a.m.
PDT on May 13, 2004. A replay of the webcast will be available at the
Company's website for 90 days. Registration and Windows(TM) Media Player is
required to view the webcast.
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and select other diseases. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by
Company founder, Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R),
currently in Phase II, is being developed as a treatment for people with HIV.
The Company has initiated development of a new IBT, IR103, which incorporates
a second-generation immunostimulatory oligonucleotide adjuvant.
The Immune Response Corporation is also developing an IBT for multiple
sclerosis (MS), NeuroVax(TM), which is currently in Phase II and has shown
potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
http://www.imnr.com.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
silver@sambrown.com
INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
kwaller@financialrelationsboard.com
AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
info@imnr.com
SOURCE Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
media, Laura Silver of Sam Brown Inc.
Corporate Communications, +1-310-551-9940, silver@sambrown.com;
investors, Kathy Waller of Financial Relations Board,
+1-312-266-7800, kwaller@financialrelationsboard.com, both for
Immune Response Corporation; or Michael K. Green, Chief Financial
Officer of Immune Response Corporation, +1-760-431-7080,
info@imnr.com
|
